Volume 64, Issue 6, Pages (December 2013)

Slides:

Advertisements

Similar presentations

Volume 64, Issue 5, Pages (November 2013)

Advertisements

Volume 53, Issue 3, Pages (March 2008)

The PSA Era is not Over for Prostate Cancer

Volume 51, Issue 2, Pages (February 2007)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 58, Issue 4, Pages (October 2010)

Long-term outcomes of dose-escalated intensity modulated radiation therapy alone without androgen deprivation therapy for patients with intermediate and.

Testosterone Therapy in Men With Prostate Cancer

Volume 53, Issue 4, Pages (April 2008)

Prostate Cancer: Highlights from 2006

Claude C. Schulman, Jacques Irani, Juan Morote, Jack A

Volume 53, Issue 5, Pages (May 2008)

Control of Prostate Cancer by Transrectal HIFU in 227 Patients

Volume 69, Issue 1, Pages (January 2016)

Volume 65, Issue 5, Pages (May 2014)

Volume 60, Issue 6, Pages (December 2011)

Volume 53, Issue 5, Pages (May 2008)

Volume 71, Issue 5, Pages (May 2017)

Hormone Therapy for Prostate Cancer: Exploring Current Controversies

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Volume 52, Issue 4, Pages (October 2007)

Volume 72, Issue 5, Pages (November 2017)

Volume 64, Issue 5, Pages (November 2013)

Tumour Grade, Treatment, and Relative Survival in a Population-based Cohort of Men with Potentially Curable Prostate Cancer Sam Ladjevardi, Gabriel Sandblom,

Volume 54, Issue 4, Pages (October 2008)

Volume 71, Issue 1, Pages 1-3 (January 2017)

What is New in Hormone Therapy for Prostate Cancer in 2007?

Prostate Cancer Detection: A View of the Future

Volume 74, Issue 1, Pages (July 2018)

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 68, Issue 3, Pages (September 2015)

Volume 67, Issue 3, Pages (March 2015)

Volume 56, Issue 2, Pages (August 2009)

Volume 67, Issue 6, Pages (June 2015)

Volume 71, Issue 5, Pages (May 2017)

Laurent Boccon-Gibod European Urology Supplements

The PSA Era is not Over for Prostate Cancer

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

External Beam Radiotherapy as Curative Treatment of Prostate Cancer

Volume 74, Issue 2, Pages (August 2018)

Volume 53, Issue 4, Pages (April 2008)

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Volume 58, Issue 1, Pages 1-7 (July 2010)

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study Stephen H. Culp, Paul.

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

Volume 73, Issue 2, Pages (February 2018)

Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial

Volume 50, Issue 5, Pages (November 2006)

Risk Factors for the Development of Bone Metastases in Prostate Cancer

Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer– specific Mortality: Competition Between Age and Time to Biochemical Failure

Volume 71, Issue 5, Pages (May 2017)

What's New in Prostate Cancer: Highlights from Urologic and Oncologic Congresses in 2006 Michel Soulié, Nicolas Mottet, Laurent Salomon, Jacques Irani,

Jacques Irani European Urology Supplements

Volume 66, Issue 6, Pages (December 2014)

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Long-Term Hormonal Therapy: Who Would Benefit?

Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Volume 74, Issue 6, Pages (December 2018)

Axel Heidenreich European Urology Supplements

Improving Flexibility and Quality of Life for Your Patients: A Must?

Volume 53, Issue 6, Pages (June 2008)

Management of Prostate Cancer: Global Strategies

Volume 53, Issue 2, Pages (February 2008)

Volume 51, Issue 2, Pages (February 2007)

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Axel Heidenreich European Urology Supplements

Volume 54, Issue 1, Pages (July 2008)

Volume 51, Issue 5, Pages (May 2007)

Presentation transcript:

Volume 64, Issue 6, Pages 895-902 (December 2013) A New Risk Classification System for Therapeutic Decision Making with Intermediate- risk Prostate Cancer Patients Undergoing Dose-escalated External-beam Radiation Therapy Zachary S. Zumsteg, Daniel E. Spratt, Isaac Pei, Zhigang Zhang, Yoshiya Yamada, Marisa Kollmeier, Michael J. Zelefsky European Urology Volume 64, Issue 6, Pages 895-902 (December 2013) DOI: 10.1016/j.eururo.2013.03.033 Copyright © 2013 European Association of Urology Terms and Conditions

Fig. 1 A comparison of favorable versus unfavorable intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy showing significant differences in (a) prostate-specific antigen (PSA) recurrence-free survival, (b) local failure, (c) distant metastasis (DM), and (d) prostate cancer–specific mortality (PCSM). European Urology 2013 64, 895-902DOI: (10.1016/j.eururo.2013.03.033) Copyright © 2013 European Association of Urology Terms and Conditions

Fig. 2 Outcomes with no unfavorable risk factors (RFs), one unfavorable RF, or two or three unfavorable RFs (ie, Gleason 4+3=7, ≥50% of biopsy cores with cancer, or more than one intermediate risk factor): (a) prostate-specific antigen (PSA) recurrence-free survival, (b) local failure, (c) distant metastasis (DM), and (d) prostate cancer–specific mortality (PCSM). European Urology 2013 64, 895-902DOI: (10.1016/j.eururo.2013.03.033) Copyright © 2013 European Association of Urology Terms and Conditions

Supplementary Fig. 1 – A comparison of low-risk and favorable intermediate-risk (IR) prostate cancer patients undergoing dose-escalated external-beam radiation therapy showing no significant difference in (a) prostate-specific antigen (PSA) recurrence-free survival, (b) distant metastasis (DM), and (c) prostate cancer–specific mortality (PCSM). European Urology 2013 64, 895-902DOI: (10.1016/j.eururo.2013.03.033) Copyright © 2013 European Association of Urology Terms and Conditions

Supplementary Fig. 2 – Prostate cancer–specific mortality (PCSM) in (a) favorable or (b) unfavorable intermediate-risk prostate cancer with and without neoadjuvant and concurrent androgen-deprivation therapy (ADT). European Urology 2013 64, 895-902DOI: (10.1016/j.eururo.2013.03.033) Copyright © 2013 European Association of Urology Terms and Conditions

Supplementary Fig. 3 – A comparison of high-risk and intermediate-risk (IR) patients with two or three unfavorable risk factors (URFs) undergoing dose-escalated external-beam radiation therapy showing no significant difference in (a) prostate-specific antigen (PSA) recurrence-free survival, (b) distant metastasis (DM), and (c) prostate cancer–specific mortality (PCSM). European Urology 2013 64, 895-902DOI: (10.1016/j.eururo.2013.03.033) Copyright © 2013 European Association of Urology Terms and Conditions